Carocell Bio is dedicated to developing new therapies for the treatment of inflammatory diseases.

Carocell Bio is dedicated to developing new therapies for the treatment of inflammatory diseases. Download presentation

COVID-19: The spread of coronavirus is affecting everyone and our thanks and very best wishes go out to all those helping others, including NHS staff, allied emergency services and anybody playing their part in keep the country and world going. read more

Carocell Bio is developing novel combination medicines that have the potential to provide safer and more effective approaches to the management of serious inflammatory conditions, including atopic dermatitis, inflammatory bowel disease and burns.

Research is focused on reducing over-activation of the intracellular inflammatory cascade. By therapeutically engaging with this process, it is possible to reduce the release of inflammatory cytokines and other inflammatory molecules and so ease inflammation.

Carocell Bio’s therapeutic molecules are short proteins (“peptides”) that are highly selective for p38α, an important component in this intracellular inflammation cascade. Combining these peptides with an established nano-polymer delivery system enhances delivery into the cells. The treatments are designed to be delivered topically rather than systemically and the peptides are simply broken down into amino acids so they are likely to provide a much safer option compared with existing therapies.

Download the latest presentation slides

Learn more about our research 

Learn more about investment opportunities

Interview with Mike Davies, CEO

DR. MIKE DAVIES TALKING ABOUT CAROCELL BIO'S WORK

INTERVIEW WITH DR. MIKE DAVIES AT BIOTECH SHOWCASE

UK Office

Carocell Bio Ltd.
28a London Rd
Alderley Edge
Macclesfield
SK9 7DZ
UK

Copyright Carocell Bio Ltd. ^©2020